Oncology's Trojan Horse: Using Viruses to Battle Cancer

Area of Science:

• Oncology
• Virology
• Biotechnology

Background:

• Cancer affects over 1.6 million Americans annually, disproportionately impacting individuals over 65.
• Older adults often face adverse events with traditional cancer treatments like chemotherapy and radiation.
• Virotherapy, utilizing oncolytic viruses (OVs), emerges as a novel therapeutic strategy.

Purpose of the Study:

• To explore the potential of virotherapy as a novel cancer treatment strategy.
• To highlight the successes and challenges of oncolytic viruses (OVs) in cancer therapy.
• To identify patient populations that may benefit from emerging virotherapy approaches.

Main Methods:

• Review of current research on oncolytic virus (OV) therapy.
• Analysis of approved OVs, including talimogene laherparepvec (T-Vec).
• Evaluation of patient response to T-Vec based on treatment history and patient characteristics.

Main Results:

• Oncolytic viruses (OVs) demonstrate success in targeting and killing cancer cells, with notable efficacy in acute lymphocytic leukemia.
• Four genetically engineered OVs are approved globally; T-Vec is the only one available in the US.
• Treatment-naive patients and elderly patients intolerant to checkpoint inhibitors show better response to T-Vec.

Conclusions:

• Oncolytic viruses (OVs) represent a promising frontier in cancer treatment, particularly for elderly patients.
• Further research is needed to enhance the clinical potency of OVs for broader application.
• Virotherapy holds significant potential to become an effective cancer therapy with continued development.